Roth Capital Resumes BioLineRx (BLRX) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Roth Capital Resumes BioLineRx (BLRX) at Buy

Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential

July 2, 2014 9:27 AM EDT

Roth Capital reinstates BioLineRx Ltd. (Nasdaq: BLRX) with a Buy rating and price target of $8.

Analust Joseph Pantginis issued the following commentary with the reinstatement, We believe BioLineRx is poised for growth based on a deep pipeline, risk mitigation through its early partnering business model, and partnering validation based on multiple partnerships already in hand. We believe BioLineRx has the ability to maintain a... More